268 related articles for article (PubMed ID: 11225517)
1. Effect of MAO inhibitors on the high-affinity reuptake of biogenic amines in rat subcortical regions.
Tekes K; Magyar K
Neurobiology (Bp); 2000; 8(3-4):257-64. PubMed ID: 11225517
[TBL] [Abstract][Full Text] [Related]
2. Effect of MAO inhibitors on the uptake and metabolism of dopamine in rat and human brain.
Tekes K; Tóthfalusi L; Gaál J; Magyar K
Pol J Pharmacol Pharm; 1988; 40(6):653-8. PubMed ID: 3152003
[TBL] [Abstract][Full Text] [Related]
3. Multiple, small dose administration of (-)deprenyl enhances catecholaminergic activity and diminishes serotoninergic activity in the brain and these effects are unrelated to MAO-B inhibition.
Knoll J; Miklya I
Arch Int Pharmacodyn Ther; 1994; 328(1):1-15. PubMed ID: 7893186
[TBL] [Abstract][Full Text] [Related]
4. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.
Lamensdorf I; Youdim MB; Finberg JP
J Neurochem; 1996 Oct; 67(4):1532-9. PubMed ID: 8858937
[TBL] [Abstract][Full Text] [Related]
5. In vitro effects on monoamine uptake and release by the reversible monoamine oxidase-B inhibitors lazabemide and N-(2-aminoethyl)-p-chlorobenzamide: a comparison with L-deprenyl.
Bondiolotti GP; Galva MD; Villa F; Sciaba L; Picotti GB
Biochem Pharmacol; 1995 Jun; 50(1):97-102. PubMed ID: 7605351
[TBL] [Abstract][Full Text] [Related]
6. R-(-)-deprenyl (Selegiline, Movergan) facilitates the activity of the nigrostriatal dopaminergic neuron.
Knoll J
J Neural Transm Suppl; 1987; 25():45-66. PubMed ID: 2828537
[TBL] [Abstract][Full Text] [Related]
7. [A comparison of the pharmacology of (-)-deprenyl to N-methylpropargylamine-1-aminoindane (J-508) and rasagiline, the desmethyl-analogue of J-508].
Miklya I
Neuropsychopharmacol Hung; 2008 Mar; 10(1):15-22. PubMed ID: 18771016
[TBL] [Abstract][Full Text] [Related]
8. E2011 a novel, selective and reversible inhibitor of monoamine oxidase type A.
Kagaya T; Kajiwara A; Nagato S; Akasaka K; Kubota A
J Pharmacol Exp Ther; 1996 Jul; 278(1):243-51. PubMed ID: 8764357
[TBL] [Abstract][Full Text] [Related]
9. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.
Gal S; Zheng H; Fridkin M; Youdim MB
J Neurochem; 2005 Oct; 95(1):79-88. PubMed ID: 16181414
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy.
Löscher W; Lehmann H; Teschendorf HJ; Traut M; Gross G
J Pharmacol Exp Ther; 1999 Mar; 288(3):984-92. PubMed ID: 10027835
[TBL] [Abstract][Full Text] [Related]
11. High-throughput screening for monoamine oxidase-A and monoamine oxidase-B inhibitors using one-step fluorescence assay.
Guang HM; Du GH
Acta Pharmacol Sin; 2006 Jun; 27(6):760-6. PubMed ID: 16723097
[TBL] [Abstract][Full Text] [Related]
12. [Effect of solubilization by methylethylketone of rat liver mitochondrial monoamine oxidase on inhibition by clorgyline and deprenyl of the enzyme activity].
Severina IS; Klimova GI; Nersisian AA
Biokhimiia; 1981 Nov; 46(11):2043-55. PubMed ID: 6797482
[TBL] [Abstract][Full Text] [Related]
13. (-)-Trans-epsilon-viniferin, a polyphenol present in wines, is an inhibitor of noradrenaline and 5-hydroxytryptamine uptake and of monoamine oxidase activity.
Yáñez M; Fraiz N; Cano E; Orallo F
Eur J Pharmacol; 2006 Aug; 542(1-3):54-60. PubMed ID: 16828740
[TBL] [Abstract][Full Text] [Related]
14. N-propargylbenzylamine, a major metabolite of pargyline, is a potent inhibitor of monoamine oxidase type B in rats in vivo: a comparison with deprenyl.
Karoum F
Br J Pharmacol; 1987 Feb; 90(2):335-45. PubMed ID: 3103805
[TBL] [Abstract][Full Text] [Related]
15. [Effect of protein denaturing reactions on retardation of the activity of rat liver mitochondrial monoamine oxidase by clorgyline and deprenyl].
Severina IS
Biokhimiia; 1983 Sep; 48(9):1513-21. PubMed ID: 6414536
[TBL] [Abstract][Full Text] [Related]
16. Effects of selective monoamine oxidase (MAO) inhibitors on conditioned avoidance responses (CAR) of rats.
Timár J; Knoll B; Gyarmati Z; Knoll J
Pol J Pharmacol Pharm; 1979; 31(4):251-60. PubMed ID: 523335
[TBL] [Abstract][Full Text] [Related]
17. L-methamphetamine and selective MAO inhibitors decrease morphine-reinforced and non-reinforced behavior in rats; Insights towards selegiline's mechanism of action.
He S; Grasing K
Pharmacol Biochem Behav; 2006 Dec; 85(4):675-88. PubMed ID: 17157368
[TBL] [Abstract][Full Text] [Related]
18. Effect of co-administration of subchronic lithium pretreatment and acute MAO inhibitors on extracellular monoamine levels and the expression of contextual conditioned fear in rats.
Kitaichi Y; Inoue T; Nakagawa S; Izumi T; Koyama T
Eur J Pharmacol; 2006 Feb; 532(3):236-45. PubMed ID: 16487506
[TBL] [Abstract][Full Text] [Related]
19. Acute effects of moclobemide and deprenyl on 5-HT synthesis rates in the rat brain: An autoradiographic study.
Nishi K; Mück-Seler D; Hasegawa S; Watanabe A; Diksic M
Brain Res Bull; 2006 Oct; 70(4-6):368-77. PubMed ID: 17027772
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of MAO-A activity enhances behavioural activity of rats assessed using water maze and open arena tasks.
Barbelivien A; Nyman L; Haapalinna A; Sirviö J
Pharmacol Toxicol; 2001 Jun; 88(6):304-12. PubMed ID: 11453370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
